Moderna Doses First Patients in Phase 2 Study of COVID-19 Vaccine - COVID-19 Clinical Trial
Breaking News | COVID-19

Moderna Doses First Patients in Phase 2 Study of COVID-19 Vaccine

Moderna recently announced that the first participants in each age cohort have been dosed in the company’s Phase 2 study of two potential COVID-19 vaccines that use its mRNA vaccine candidate, mRNA-1273.The Phase 2 study intends to evaluate the safety, reactogenicity, and immunogenicity of two vaccinations of mRNA-1273. These will be given 28 days apart, Moderna said. 

The biotechnology company, which pioneers in messenger RNA therapeutics and vaccines, intends to enroll 600 participants in two groups: adults aged 18 to 55 years of age and older adults aged 55 and older. The two groups will individually receive 50 μg or a 100 μg dose of both vaccinations. Experts will follow up with participants 12 months after the second vaccination. 

iBio Announces Second COVID-19 Vaccine Program

iBio, Inc. , a biotechnology innovator and biologics contract manufacturing organization, today announced initiation of preclinical immunization studies for its second COVID-19 vaccine platform.The new subunit vaccine (“IBIO-201”) combines antigens derived from the SARS-CoV-2 spike protein fused with the Company’s patented lichenase booster molecule (“LicKM”), which is designed to enhance immune response. The addition of the LicKM booster to a subunit antigen is expected to improve the likelihood of achieving single-dose, prolonged immunity while also increasing manufacturing capacity through increased potency.

“The launch of our second COVID-19 vaccine program is emblematic of the speed, flexibility and scalability we can achieve by combining our plant-based FastPharming System™ with other technologies in our intellectual property portfolio, such as LicKM,” said Tom Isett, Co-Chairman & CEO of iBio. “As a company with purpose-built pandemic response capabilities, we are pleased that in a matter of weeks we successfully discovered and advanced two promising, unique, internally-developed, COVID-19 vaccine programs into IND-enabling studies. Equally important is that our plant-based system avoids resource-intensive scale-up challenges associated with traditional manufacturing approaches so that we should be able to more rapidly produce high-quality material for hundreds of millions of doses upon regulatory clearance.”

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.